Unable to raise the cash needed to sustain operations, after all assets were sold to Integra Life Sciences -- another SBIR involved firm -- in 2003 Neuron Therapeutics closed it doors . The firm had been engaged in the development of proprietary new drugs and delivery technologies for the treatment of disorders of the central nervous system. Focused on applying its novel drug and delivery system to the treatment of stroke, subarachnoid hemorrhage and other central nervous system diseases Neuronwas trying to commercialize a novel brain protection technology developed over the past 15 years at Thomas Jefferson University Medical Center (Philadelphia). The technology involved using the Cerebral Spinal Fluid space to bathe the brain after a severe stroke with oxygen, nutrients and also achieve hypothermia.
